About Careers MedBlog Contact us

Novartis Japan Hit With 15-day Suspension for Failing to Report Drug Side Effects

by Dr. Trupti Shirole on March 1, 2015 at 5:14 AM
Font : A-A+

 Novartis Japan Hit With 15-day Suspension for Failing to Report Drug Side Effects

The Japanese unit of Swiss pharmaceutical giant Novartis has been ordered to temporarily suspend its operations for failing to report drug side effects, revealed the health ministry. This is reportedly a first for a pharmaceutical firm operating in Japan. During the 15-day suspension, which is to start from March 5, the company will not be able to sell most of its drugs.

Drug-makers are required to report serious side effects of any drugs to the ministry within 15 to 30 days. In July 2014, Tokyo-based Novartis Pharma K.K., was handed a business improvement order for failing to properly report side effects of two leukaemia drugs. Also, the prosecutors laid charges against the unit over claims that falsified data were used to exaggerate the benefits of a popular blood-pressure drug. They also indicted a former employee, Nobuo Shirahashi, alleging he manipulated the data in clinical studies that were later used in marketing the drug Diovan (Valsartan).


In December 2014, Novartis admitted to have failed to promptly report more than 3,000 cases of adverse effects from about two dozen company drugs.

Source: Medindia


Recommended Reading

Latest Drug News

 Parkinson's Unmet Needs Creates Path for New Entrants into the Market
Addressing the unmet needs of Parkinson's Disease by providing disease-modifying therapies could bring about a major shift in the way that patients are treated.
How Microrobots Could Help Treat Bladder Diseases?
Microrobots could swirl through a person's blood stream, search for targeted areas to treat for various ailments.
How Can Multivitamin Supplements Slow Cognitive Aging?
Supplementation with multivitamins is an inexpensive way for older adults to slow down memory loss.
 Ivosidenib Approved for Acute Myeloid Leukemia & Advanced Cholangiocarcinoma
Some people with an aggressive blood cancer called acute myeloid leukemia (AML) may soon have a new drug option called Ivosidenib that blocks the activity of IDH1 gene.
Sacubitril/valsartan Unleashes Hope for Heart Failure Patients
In case of cardiac failure where the ejection fraction is greater than 40%, sacubitril/valsartan can prove to be quite beneficial
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Novartis Japan Hit With 15-day Suspension for Failing to Report Drug Side Effects Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests